Zoetis Inc. (NYSE:ZTS – Get Free Report) has received a consensus recommendation of “Hold” from the fifteen ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $133.0833.
ZTS has been the topic of a number of research reports. Stifel Nicolaus dropped their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Citigroup dropped their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. JPMorgan Chase & Co. decreased their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, William Blair restated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd.
Zoetis Stock Performance
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the company posted $1.48 EPS. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts expect that Zoetis will post 6.88 EPS for the current fiscal year.
Zoetis Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.
Insider Activity
In related news, Director Michael B. Mccallister acquired 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 11,650 shares of company stock valued at $886,384. Insiders own 0.22% of the company’s stock.
Institutional Trading of Zoetis
A number of institutional investors and hedge funds have recently modified their holdings of ZTS. Brighton Jones LLC increased its position in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the period. Empowered Funds LLC increased its position in shares of Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC increased its position in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC increased its position in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares during the period. Finally, Glenview Trust co increased its position in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after purchasing an additional 506 shares during the period. 92.80% of the stock is currently owned by institutional investors.
About Zoetis
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Stories
- Five stocks we like better than Zoetis
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
